Biotech Valneva eyes growth inflection with Covid vaccine
CEO Thomas Lingelbach confident of European approval, but shuns 'pandemic stock' label.
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
FRENCH biotech Valneva, a manufacturer of vaccines for travellers, was once a sleepy stock, with a market capitalisation of just 236.8 million euros (S$351.8 million) in end-2019. But entering the Covid-19 vaccine race has swept it into the public eye.
In 2020, Valneva unveiled plans to develop a Covid-19 vaccine based on the more mature non-mRNA technology. It has since faced many ups and downs, from positive trial results and emergency approval in Bahrain, to a cancelled contract with the United Kingdom.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Japan stocks look set for new highs in 2025 on earnings, reform
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
